Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Black Widow Spider Antivenin for Patients With Systemic Latrodectism (BWS P3)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Instituto Bioclon S.A. de C.V.
Rare Disease Therapeutics Inc.
Information provided by (Responsible Party):
Instituto Bioclon S.A. de C.V. Identifier:
First received: April 9, 2008
Last updated: May 22, 2014
Last verified: May 2014

The purpose of this study is to test the effectiveness and safety of a new antivenom called Analatro® for treating black widow spider bites in patients who present to a hospital emergency room within 24 hours of symptom onset. This study will be a phase III, multi-center, double-blind, randomized controlled study that takes place in emergency departments. The primary aim of this study is to determine the proportion of patients in which pain control was not achieved by 48 hours post treatment. Secondary aims are as follows: 1) a reduction in pain intensity at the end of the treatment phase compared to baseline; 2) the proportion of patients with a clinically significant decrease in pain intensity at 30 minutes post-treatment; 3) the proportion of patients in which drug-related adverse events occurred; and 4) to determine if serious, drug-related adverse events in Analatro-treated patients occurred at a rate greater than one in 10 (10%).

Condition Intervention Phase
Drug: Analatro
Drug: Saline
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III Multicenter Clinical Trial of Analatro® [Antivenin Latrodectus (Black Widow) Equine Immune F(ab)2] in Patients With Systemic Latrodectism

Further study details as provided by Instituto Bioclon S.A. de C.V.:

Primary Outcome Measures:
  • Pain Control [ Time Frame: 48 hours post treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Serious, drug-related adverse events [ Time Frame: 17 days post treatment ] [ Designated as safety issue: Yes ]
  • Reduction in pain intensity [ Time Frame: End of treatment phase ] [ Designated as safety issue: No ]
  • Reduction in pain intensity [ Time Frame: 30 minutes post treatment ] [ Designated as safety issue: No ]
  • Drug-related adverse events [ Time Frame: 17 days post treatment ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 56
Study Start Date: August 2009
Estimated Study Completion Date: November 2014
Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Antivenin Latrodectus (Black Widow) Equine Immune F(ab)2
Drug: Analatro
30 mL of lyophilized antivenom, reconstituted in 50 mL saline infused over 10 minutes, up to 2 doses
Other Name: Analatro
Placebo Comparator: 2
Normal Saline
Drug: Saline
50 mL of saline infused over 10 minutes
Other Name: Placebo

  Show Detailed Description


Ages Eligible for Study:   10 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Moderate to severe pain intensity measured using the visual analog scale (VAS score ≥ 40mm) at the start of screening phase (VAS 0)
  • Diagnosis of latrodectism by the Investigator, with concurrence of diagnosis by a physician not directly involved with the study
  • Moderate to severe pain intensity measured using the visual analog scale (VAS score ≥ 40mm) at Baseline (VAS 1)

Exclusion Criteria:

  • Less than 10 years of age
  • Presents to the emergency department of any healthcare facility greater than 24 hours after onset of symptoms
  • Has a known (self-reported) hypersensitivity to fentanyl, morphine, diazepam, or equine serum
  • History of significant cardiac, respiratory, hepatic or renal disease, psychiatric disorder or chronic pain syndrome that in the investigator's assessment would confound efficacy or safety endpoint assessment (e.g., a bite to the leg of a patient with reflex sympathetic dystrophy)
  • History or suspected history or substance abuse
  • Pregnant or breast-feeding
  • Has a distracting injury with acute pain, or is unable to make a reliable self-report of pain intensity to pain relief based solely on the condition of interest
  • Was already treated with Merck Antivenin Latrodectus Mactans for signs/symptoms related to the current widow spider bite
  • Unable to provide a telephone number to be contacted for follow-up interviews on Days 2, 10, and 17 after discharge from the emergency department
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00657540

Contact: Kim Fields, MS 303-389-1862
Contact: Victoria Anderson, MPH CCRP CCRC 303-389-1236

United States, Arizona
Banner Good Samaritan Medical Center Recruiting
Phoenix, Arizona, United States, 85006
Contact: Angie Padilla-Jones, RN, BSN    602-839-3590   
Principal Investigator: Anne-Michelle Ruha, MD         
Maricopa Medical Center Recruiting
Phoenix, Arizona, United States, 85008
Contact: Mary Mulrow, RN, MN    602-344-5058   
Principal Investigator: Dan Quan, MD         
United States, California
University of California Davis Recruiting
Davis, California, United States, 95616
Contact: Shari Nichols   
Principal Investigator: Mark Sutter, MD         
University California San Francisco - Fresno Active, not recruiting
Fresno, California, United States, 93701
University of California Irvine Recruiting
Irvine, California, United States, 92697
Contact: Jeffery Suchard, MD   
Principal Investigator: Jeff Suchard, MD         
Loma Linda University Recruiting
Loma Linda, California, United States, 92354
Contact: Sarah Pearl   
Principal Investigator: Sean Bush, MD         
San Diego Children's Hospital Recruiting
San Diego, California, United States, 92123
Contact: Alicia Minns   
Principal Investigator: Rick Clark, MD         
University of California San Diego Recruiting
San Diego, California, United States, 92103
Contact: Alicia Minns   
Principal Investigator: Rick Clark, MD         
United States, Colorado
University of Colorado Hospital Recruiting
Aurora, Colorado, United States, 80010
Contact: Torie Anderson, MPH   
Principal Investigator: Kennon Heard, MD         
Denver Health and Hospital Authority Recruiting
Denver, Colorado, United States, 80204
Contact: Torie Anderson, MPH   
Principal Investigator: Kennon Heard, MD         
United States, Florida
Cape Coral Hospital Recruiting
Cape Coral, Florida, United States, 33990
Contact: Michael Schultz, MD         
Principal Investigator: Michael Schultz, MD         
University of Florida, Department of Emergency Medicine Recruiting
Gainesville, Florida, United States, 32610
Contact: Kelly Jackman, PhD, MT (ASCP)    352-265-5911   
Principal Investigator: David Meurer, MD         
United States, Louisiana
LSU Health Sciences Recruiting
Shreveport, Louisiana, United States, 71106
Contact: Kim Hutchinson   
Principal Investigator: Thomas Arnold, MD         
United States, New Mexico
University of New Mexico Recruiting
Albuquerque, New Mexico, United States, 87131
Contact: Silas Bussman, MPH   
Principal Investigator: Steve Seifert, MD         
United States, Texas
Texas Tech - West Texas Regional Poison Center Recruiting
El Paso, Texas, United States, 79905
Contact: Sal Baeza   
Principal Investigator: John Haynes, MD         
United States, Virginia
University of Virginia Health System Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Lea Becker   
Principal Investigator: Chris Holstege, MD         
Sponsors and Collaborators
Instituto Bioclon S.A. de C.V.
Rare Disease Therapeutics Inc.
Principal Investigator: Richard C Dart, MD, PhD Rocky Mountain Poison & Drug Center - Denver Health
Study Director: Walter Garcia, MD Instituto Bioclon S.A. de C.V.
  More Information

No publications provided

Responsible Party: Instituto Bioclon S.A. de C.V. Identifier: NCT00657540     History of Changes
Other Study ID Numbers: XF-07/03
Study First Received: April 9, 2008
Last Updated: May 22, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Instituto Bioclon S.A. de C.V.:
black widow spider

Additional relevant MeSH terms:
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs processed this record on February 25, 2015